Inotersen
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
FAP
Conditions
FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Trial Timeline
Jun 26, 2014 → Jan 7, 2021
NCT ID
NCT02175004About Inotersen
Inotersen is a phase 3 stage product being developed by Ionis Pharmaceuticals for FAP. The current trial status is completed. This product is registered under clinical trial identifier NCT02175004. Target conditions include FAP, Familial Amyloid Polyneuropathy, TTR.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03400098 | Pre-clinical | Completed |
| NCT02175004 | Phase 3 | Completed |
Competing Products
2 competing products in FAP
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Celecoxib | Pfizer | Pre-clinical | 18 |
| Inotersen + Placebo | Ionis Pharmaceuticals | Phase 2/3 | 35 |